Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of Leukocyte Biology"
DOI: 10.1002/jlb.5ri0220-603rr
Abstract: The goal of precision immunotherapy is to direct a patient's T cell response against the immunogenic mutations expressed on their tumors. Most immunotherapy approaches to‐date have focused on MHC class I‐restricted peptide epitopes by which…
read more here.
Keywords:
cd4 cells;
immunotherapy;
cells cancer;
cancer immunotherapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.10.003
Abstract: Therapies that utilize immune checkpoint inhibition work by leveraging mutation-derived neoantigens and have shown greater clinical efficacy in tumors with higher mutational burden. Whether tumors with a low mutational burden are susceptible to neoantigen-targeted therapy…
read more here.
Keywords:
neoantigen specific;
low mutational;
specific cells;
burden ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz253.054
Abstract: Abstract Background Immune checkpoint inhibitors are an important therapy. However, their essence is nonspecific and efficiency of single usage is not satisfactory. The mutant neoantigen specific T (Nas-T) cell, as an adoptive cell treatment, is…
read more here.
Keywords:
neoantigen;
neoantigen specific;
cell personalized;
personalized immunotherapy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abo7604
Abstract: Upon chronic antigen exposure, CD8+ T cells become exhausted, acquiring a dysfunctional state correlated with the inability to control infection or tumor progression. In contrast, stem-like CD8+ T progenitors maintain the ability to promote and…
read more here.
Keywords:
cell;
tumor;
neoantigen specific;
cd8 cells ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005328
Abstract: Background Merkel cell carcinoma (MCC) often responds to PD-1 pathway blockade, regardless of tumor-viral status (~80% of cases driven by the Merkel cell polyomavirus (MCPyV)). Prior studies have characterized tumor-specific T cell responses to MCPyV,…
read more here.
Keywords:
cell;
response;
cd4 cells;
neoantigen specific ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-4055
Abstract: There is strong evidence that immunotherapy-mediated tumor rejection can be driven by the reinvigoration of tumor-specific CD8+ T cells recognizing neoantigens derived from tumor somatic mutations (citations). Thus, it is possible that the relative abundance…
read more here.
Keywords:
specific cd8;
cd8 cells;
cd8;
specific cells ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Genome Medicine"
DOI: 10.1186/s13073-019-0697-8
Abstract: BackgroundThe efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of…
read more here.
Keywords:
neoantigen;
mutation burden;
neoantigen specific;
colorectal cancers ... See more keywords